<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619900</url>
  </required_header>
  <id_info>
    <org_study_id>21-34933</org_study_id>
    <nct_id>NCT05619900</nct_id>
  </id_info>
  <brief_title>Registry of Patients Diagnosed With Lysosomal Storage Diseases</brief_title>
  <acronym>LSD Registry</acronym>
  <official_title>Registry of Patients Diagnosed With Lysosomal Storage Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international prospective and retrospective registry of patients with Lysosomal&#xD;
      Storage Diseases (LSDs) to understand the natural history of the disease and the outcomes of&#xD;
      fetal therapies, with the overall goal of improving the prenatal management of patients with&#xD;
      LSDs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The need for methods to track patient outcomes, clinical management, medical decision making,&#xD;
      and quality of care are all part of current national mandates in patient safety and quality&#xD;
      of care delivery.&#xD;
&#xD;
      The aim of this registry is to prospectively and retrospectively collect data on patients who&#xD;
      are diagnosed with Lysosomal Storage Disease and other LSD mutations. Data collected will be&#xD;
      used to:&#xD;
&#xD;
        1. Identify patient outcomes of therapies.&#xD;
&#xD;
        2. Improve clinical management of patients with LSDs.&#xD;
&#xD;
        3. Improve medical decision making.&#xD;
&#xD;
        4. Improve quality of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2022</start_date>
  <completion_date type="Anticipated">May 31, 2050</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2050</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Number of patients with and types of prenatal features of Lysosomal Storage Diseases</measure>
    <time_frame>15 years</time_frame>
    <description>Prenatal presentation of symptoms (e.g. hydrops) appearing on fetal imaging such as ultrasound and ECHO.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with the presence and levels of glycosaminoglycans (GAGs) in urine.</measure>
    <time_frame>15 years</time_frame>
    <description>Laboratory analysis of urine for GAG levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants that show measured levels of antibodies against the enzyme.</measure>
    <time_frame>15 years</time_frame>
    <description>Laboratory analysis of blood to measure antibody levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants that show functional cardiac, growth, mobility, and neurocognitive function.</measure>
    <time_frame>15 years</time_frame>
    <description>echocardiogram, skeletal survey, neurocognitive assessments such as Bayley III to assess cardiac, growth, mobility and neurocognitive function.</description>
  </primary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Mucopolysaccharidosis I</condition>
  <condition>Mucopolysaccharidosis II</condition>
  <condition>Mucopolysaccharidosis IV A</condition>
  <condition>Mucopolysaccharidosis VI</condition>
  <condition>Mucopolysaccharidosis VII</condition>
  <condition>Pompe Disease Infantile-Onset</condition>
  <condition>Neuronopathic Gaucher Disease</condition>
  <condition>Wolman Disease</condition>
  <arm_group>
    <arm_group_label>Mucopolysaccharidosis I</arm_group_label>
    <description>Prenatally or postnatally diagnosed individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucopolysaccharidosis II</arm_group_label>
    <description>Prenatally or postnatally diagnosed individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucopolysaccharidosis IV A</arm_group_label>
    <description>Prenatally or postnatally diagnosed individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucopolysaccharidosis VI</arm_group_label>
    <description>Prenatally or postnatally diagnosed individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucopolysaccharidosis VII</arm_group_label>
    <description>Prenatally or postnatally diagnosed individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infantile-Onset Pompe Disease</arm_group_label>
    <description>Prenatally or postnatally diagnosed individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuronopathic Gaucher</arm_group_label>
    <description>Prenatally or postnatally diagnosed individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wolman Disease</arm_group_label>
    <description>Prenatally or postnatally diagnosed individuals</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>There is no intervention</intervention_name>
    <description>This is an observational study. There is no intervention. The purpose of the project is to create a database of patients diagnosed either prenatally or after birth with a lysosomal storage disease. The database will be utilized to assess patient outcomes, build on existing clinical management, improve medical decision making, and improve quality of care.</description>
    <arm_group_label>Infantile-Onset Pompe Disease</arm_group_label>
    <arm_group_label>Mucopolysaccharidosis I</arm_group_label>
    <arm_group_label>Mucopolysaccharidosis II</arm_group_label>
    <arm_group_label>Mucopolysaccharidosis IV A</arm_group_label>
    <arm_group_label>Mucopolysaccharidosis VI</arm_group_label>
    <arm_group_label>Mucopolysaccharidosis VII</arm_group_label>
    <arm_group_label>Neuronopathic Gaucher</arm_group_label>
    <arm_group_label>Wolman Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prenatal or postnatal patients diagnosed with a Lysosomal Storage Disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 0-64 with a diagnosis of a lysosomal storage disease&#xD;
&#xD;
          -  Pregnant patients whose fetus has a diagnosis of a lysosomal storage disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There are no current exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tippi C MacKenzie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Billie Lianoglou, MS</last_name>
    <phone>415-476-2461</phone>
    <email>billie.lianoglou@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emma Canepa, MS, CCRP</last_name>
    <phone>415-476-7255</phone>
    <email>Emma.Canepa@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Billie Lianoglou, MS</last_name>
      <phone>415-476-2461</phone>
      <email>billie.lianoglou@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emma Canepa, MS, CCRP</last_name>
      <phone>415-476-7255</phone>
      <email>Emma.Canepa@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tippi C MacKenzie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lysosomal Storage Disease</keyword>
  <keyword>LSDs</keyword>
  <keyword>Inborn Error of Metabolism</keyword>
  <keyword>Hurler Syndrome</keyword>
  <keyword>Sly Syndrome</keyword>
  <keyword>Hunter Syndrome</keyword>
  <keyword>Mucopolysaccharidosis I</keyword>
  <keyword>Mucopolysaccharidosis II</keyword>
  <keyword>Mucopolysaccharidosis IVa</keyword>
  <keyword>Mucopolysaccharidosis VI</keyword>
  <keyword>Mucopolysaccharidosis VII</keyword>
  <keyword>Pompe Disease Infantile-Onset</keyword>
  <keyword>Neuronopathic Gaucher Disease</keyword>
  <keyword>Wolman Disease</keyword>
  <keyword>MPS</keyword>
  <keyword>Mucopolysaccharidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteochondrodysplasias</mesh_term>
    <mesh_term>Gaucher Disease</mesh_term>
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Wolman Disease</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
    <mesh_term>Mucopolysaccharidosis IV</mesh_term>
    <mesh_term>Mucopolysaccharidosis VII</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

